Meeting
2021 ASCO Annual Meeting
KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.
Authors
Tony S. K. Mok
State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong, China
Tony S. K. Mok , William E. Lawler , Merrill Kingman Shum , Shaker R. Dakhil , Alexander I. Spira , Fabrice Barlesi , Martin Reck , Marina Chiara Garassino , David R. Spigel , Delia Alvarez , Thian Kheoh , William Paxton , Richard C. Chao , Enriqueta Felip
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04685135
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9129)
DOI
10.1200/JCO.2021.39.15_suppl.TPS9129
Abstract #
TPS9129
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.
First Author: Federico Cappuzzo
Poster
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
First Author: Gregory J. Riely
Poster
2024 ASCO Breakthrough
SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.
First Author: Makoto Nishio
Poster
2023 ASCO Annual Meeting
Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).
First Author: Anne-Marie C. Dingemans